Intelligence Profile
Safety Profile
The safety evidence for tesamorelin comes primarily from clinical trials in HIV-positive patients with lipodystrophy, with limited data available on safety in other populations or conditions.
Known Side Effects
Based on available clinical trial data, tesamorelin appears to have a generally manageable side effect profile, though comprehensive safety data across all populations is limited. The evidence shows tesamorelin has been studied in several completed clinical trials (NCT00795210, NCT02012556, NCT00675506, NCT02196831), but detailed adverse event profiles from these studies are not provided in the available evidence.
Evidence limitation: The current evidence does not provide specific frequencies or severity grades for adverse events, making it difficult to fully characterize the safety profile.
Contraindications
The available evidence does not provide clear information on absolute contraindications for tesamorelin use. This represents a significant gap in the safety documentation.
Drug Interactions
No specific drug interaction data is available in the provided evidence. Given tesamorelin's mechanism as a growth hormone-releasing hormone analog, potential interactions with medications affecting the growth hormone-IGF1 axis would be theoretically possible, but no concrete interaction data is documented here.
Populations That Should Exercise Caution
Based on the available evidence:
HIV-positive patients: While this population has been the primary focus of tesamorelin research, specific safety considerations within this group are not detailed in the provided evidence.
Patients with traumatic brain injury: One study (NCT02931474) investigating tesamorelin in service members with traumatic brain injury and insomnia was withdrawn, though the reasons for withdrawal are not specified in the available evidence.
General populations: The safety profile in healthy individuals or those without HIV-related lipodystrophy is not well-established based on the provided evidence.
Evidence Limitations
The safety profile of tesamorelin is poorly characterized in the available evidence. Key limitations include:
- Lack of detailed adverse event data from completed clinical trials
- Absence of contraindication information
- No documented drug interaction data
- Limited safety data in non-HIV populations
- No information on use in special populations (pregnancy, pediatrics, elderly)
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Patients considering tesamorelin should consult with their healthcare provider to discuss individual risks, benefits, and safety considerations based on their specific medical situation and current medications.
Clinical Note: Healthcare providers should consult current prescribing information and clinical guidelines for complete safety data before prescribing tesamorelin, as the available evidence reviewed here does not provide comprehensive safety documentation.